have you heard the one about the llama?

A COVID-19 research breakthrough out of a Texas university comes from unlikely source

COVID-19 antibody research coming out of the University of Texas stars an unlikely participant: A llama named Winter. University of Texas at Austin/Facebook

In the race to find a treatment for the novel coronavirus, researchers at the University of Texas at Austin have announced a potential breakthrough — thanks to a llama.

Scientists from Texas' flagship university who have been collaborating with the National Institutes of Health and Ghent University in Belgium identified an antibody treatment that could potentially neutralize the virus that causes COVID-19.

The researchers detail their work in the May 5 edition of Cell, a scientific journal.

"This is one of the first antibodies known to neutralize SARS-CoV-2," said Jason McLellan, associate professor of molecular biosciences at UT Austin and co-senior author of the paper, in a release. (FYI, SARS-CoV-2 is referring to the virus that causes COVID-19.)

Using a Belgian llama named Winter, scientists were able to identify two antibodies the animal produces when it comes into contact with a foreign body (such as the coronavirus). The first is similar to a human antibody and the second is much smaller, about one-quarter of the size of the other.

This is Winter. Photo courtesy of University of Texas at Austin

Researchers were able to link two copies of this special llama antibody to create a new antibody. This new antibody binds tightly to a key protein on the coronavirus germ that causes COVID-19 and could possible be nebulized and put into an inhaler.

"That makes them potentially really interesting as a drug for a respiratory pathogen because you're delivering it right to the site of infection," said Daniel Wrapp, a UT graduate student in McLellan's lab and co-first author of the paper.

Unlike vaccines, which can take up to two months to take effect, antibody treatment can be used in more vulnerable populations as a way to fight off the virus.

"Vaccines have to be given a month or two before infection to provide protection," McLellan said. "With antibody therapies, you're directly giving somebody the protective antibodies and so, immediately after treatment, they should be protected. The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease."

From here, research turns to preclinical studies, using hamsters and primates for testing. If successful, they will move onto humans.

If you're wondering just how a group of researchers living in different parts of the globe were able to make this discovery seemingly overnight, that's because they've actually been working on it since 2016, when Winter was just 9 months old.

The experiment began as a way to develop vaccinations for two earlier versions of the coronavirus: SARS-CoV-1 and MERS-CoV. Their years of research allowed the scientists to pivot in recent months to isolating the protein in COVID-19.

As for Winter, she's now 4 years old and still lives with about 130 llamas on a farm in Belgium, likely unaware of her contribution to potentially altering the course of COVID-19 forever.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Nauticus Robotics has been awarded another multimillion-dollar contract from the U.S. Defense Innovation Unit. Photo via nauticusrobotics.com

Webster-based Nauticus Robotics Inc., a newly minted public company, continues to make waves with government contracts.

Nauticus says it has been awarded a second multimillion-dollar contract from the U.S. Defense Innovation Unit, part of the U.S. Defense Department, for development of a self-piloted amphibious robot system powered by the company’s ToolKITT command-and-control software.

In February, Nauticus said it had been given a ToolKITT contract by the Defense Innovation Unit. Under that contract, ToolKITT is being used aboard a remotely controlled undersea vehicle operated by the Navy.

Similar contracts with the Defense Innovation Unit could be on the horizon, Nauticus says.

Nauticus develops oceangoing robots under the brand names Aquanaut and Hydronaut, along with the ToolKITT autonomy software and related services. It’s forecasting 2023 revenue of $90 million.

Driven by machine learning, ToolKITT helps identify, categorize, and perform activities that can “remove, detect, identify, inspect, and neutralize hazards underwater,” according to a Nauticus news release.

ToolKITT is used for various self-piloted robotics products, including Nauticus’ Aquanaut.

“We are humbled and honored to be doing our part to advance the usage of robotics and autonomous systems to remove servicemembers from harm’s way,” says Ed Tovar, director of business development for defense systems at Nauticus.

Nauticus’ stock began trading September 13 on the Nasdaq market. The milestone came four days after Nauticus merged with publicly traded CleanTech Acquisition Corp., a “blank check” shell company formed to acquire or merge with a business. At one point, the merger was valued at $560 million.

The new combo, operating under the Nauticus name, is led by Nauticus founder and CEO Nicolaus Radford.

“The closing of this business combination represents a pivotal milestone in our company’s history as we take public our pursuit of transforming the ocean robotics industry with autonomous systems,” Radford says in a news release. “Not only is the ocean a tremendous economic engine, but it is also the epicenter for building a sustainable future.”

Trending News